Investors
and Media
News Releases
-
May 18, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of...
-
May 14, 2020- Reinforcing Breakthrough Innovation and Clinical Value of Andexxa, Proposed Extension Will Support Patient Access by Continuing to Provide Medicare Reimbursement in the Hospital Setting -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa®...
-
May 11, 2020- Reached Agreement to be Acquired by Alexion; Transaction Expected to Close in Third Quarter -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2020, and provided a corporate update, including the Company's actions to...
-
May 5, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) (the "Company" or "Portola") today announced that it is cancelling its webcast and conference call to discuss the Company's financial results for the...
-
May 5, 2020– Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent –
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) announced today that they have entered into a...
-
May 1, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on April 30, 2020, the Compensation Committee of the Board of Directors approved, effective as of April 30, 2020, the grant to...
-
Apr 23, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2020, and...
-
Apr 7, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Centers for Medicare & Medicaid Services (CMS) established a new permanent J-code for Andexxa® [coagulation factor Xa...
-
Apr 1, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on March 31, 2020, the Compensation Committee of the Board of Directors approved, effective as of March 31, 2020, the grant to...
-
Mar 18, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public health efforts to prevent furtherspread of coronavirus (or COVID-19) around...
-
Mar 16, 2020Real-World Data Support Use of Andexxa Can Improve Outcomes
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved...
-
Mar 5, 2020- Analysis Projects Hospital Use of Andexxa with NTAP Reimbursement Can Reduce Cost Per Hospitalization by $5,400 Compared to 4F-PCC -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] to treat...
-
Mar 2, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on February 28, 2020, the Compensation Committee of the Board of Directors approved, effective as of February 28, 2020, a grant...
-
Feb 26, 2020- Full-Year 2019 Andexxa®/Ondexxya® Net Product Revenues of $111.5 Million -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the fourth quarter and full year ended December 31, 2019. "2019 was a year of significant accomplishments for...
-
Feb 24, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that the Company will participate in the following conferences in March. Cowen 40th Annual Health Care Conference on Tuesday, March...
-
Feb 12, 2020
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the fourth quarter and full year ended...
-
Feb 3, 2020- Brings to Portola 20 Years of Clinical Development and Approval Experience -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the appointment of Rajiv Patni, M.D., as executive vice president and chief medical officer, effective immediately. Dr. Patni brings...
-
Jan 9, 2020- Fourth Quarter Net Revenues of Andexxa Expected to be Approximately $28 Million Including $4 Million in Fourth Quarter Sales from Ondexxya in Europe -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced preliminary unaudited Andexxa global net revenues for the fourth quarter and full year 2019. For the fourth quarter, the Company...
-
Dec 23, 2019
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it will host an investor event to discuss expected corporate and product milestones in 2020. The event is scheduled to take place on
-
Dec 17, 2019- American Heart Association Quality Improvement Project Promotes Patient Education and Physician Best Practices for Hemorrhagic Stroke -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced its support of the American Heart Association®/American Stroke Association's® newest initiative for enhanced awareness and...
-
Dec 9, 2019- Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
Dec 8, 2019- Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
Nov 15, 2019- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...
-
Nov 6, 2019- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...
-
Nov 5, 2019- Andexxa®/Ondexxya® Net Product Revenues of $35.7 million, a 32% Increase Over the Prior Quarter -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...